{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Cancers&page=101", "query": { "condition": "Multiple Cancers", "page": 101 }, "page_size": 10 }, "pagination": { "page": 101, "page_size": 10, "total_count": 4780, "total_pages": 478, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Cancers&page=102&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Cancers&page=100&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-11T16:47:06.992Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06018337", "title": "A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "DB-1303/BNT323", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "DualityBio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 541, "start_date": "2024-01-18", "completion_date": "2028-08", "has_results": false, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-11-11T16:47:06.992Z", "location_count": 44, "location_summary": "Tucson, Arizona • Fullerton, California • Los Angeles, California + 39 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06018337" }, { "nct_id": "NCT03012880", "title": "Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Plasma Cell Myeloma" ], "interventions": [ { "name": "Daratumumab", "type": "BIOLOGICAL" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Ixazomib Citrate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2017-04-20", "completion_date": "2022-12-15", "has_results": true, "last_update_posted_date": "2025-06-04", "last_synced_at": "2026-11-11T16:47:06.992Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03012880" }, { "nct_id": "NCT04508179", "title": "A Phase 1 SAD and MAD Study of the Safety, Tolerability and PK of 7HP349 in Normal Healthy Male Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "7HP349 Single Ascending Dose", "type": "DRUG" }, { "name": "7HP349 Multiple Ascending Dose", "type": "DRUG" }, { "name": "Placebo Single Ascending Dose", "type": "DRUG" }, { "name": "Placebo Multiple Ascending Dose", "type": "DRUG" }, { "name": "7HP349 Food Effect", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "7 Hills Pharma, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "MALE", "summary": "18 Years to 45 Years · Male only" }, "enrollment_count": 60, "start_date": "2020-10-28", "completion_date": "2021-10-25", "has_results": false, "last_update_posted_date": "2021-11-02", "last_synced_at": "2026-11-11T16:47:06.992Z", "location_count": 1, "location_summary": "Secaucus, New Jersey", "locations": [ { "city": "Secaucus", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04508179" }, { "nct_id": "NCT01526096", "title": "Stem Cell Transplantation for Patients With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myeloma" ], "interventions": [ { "name": "G-CSF", "type": "DRUG" }, { "name": "Plerixafor", "type": "DRUG" }, { "name": "Apheresis", "type": "PROCEDURE" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Stem cell re-infusion", "type": "PROCEDURE" }, { "name": "Basiliximab", "type": "DRUG" }, { "name": "CliniMACS CD25 microbeads and cell sorter", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "DEVICE" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "21 Years to 70 Years" }, "enrollment_count": 30, "start_date": "2011-07-12", "completion_date": "2024-08-28", "has_results": false, "last_update_posted_date": "2025-11-05", "last_synced_at": "2026-11-11T16:47:06.992Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01526096" }, { "nct_id": "NCT00489086", "title": "Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplastic Syndrome" ], "interventions": [ { "name": "tazarotene", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UCSF Benioff Children's Hospital Oakland", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 36, "start_date": "2004-07", "completion_date": "2012-06", "has_results": true, "last_update_posted_date": "2020-10-29", "last_synced_at": "2026-11-11T16:47:06.992Z", "location_count": 2, "location_summary": "Oakland, California • New York, New York", "locations": [ { "city": "Oakland", "state": "California" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00489086" }, { "nct_id": "NCT05130060", "title": "A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Colon Adenocarcinoma", "Metastatic Colorectal Adenocarcinoma", "Metastatic Colorectal Carcinoma", "Metastatic Microsatellite Stable Colon Carcinoma", "Metastatic Microsatellite Stable Colorectal Carcinoma", "Metastatic Rectal Adenocarcinoma", "Microsatellite Stable Rectal Carcinoma", "Stage IV Colorectal Cancer AJCC v8", "Stage IVA Colorectal Cancer AJCC v8", "Stage IVB Colorectal Cancer AJCC v8", "Stage IVC Colorectal Cancer AJCC v8" ], "interventions": [ { "name": "Colorectal Cancer Peptide Vaccine PolyPEPI1018", "type": "BIOLOGICAL" }, { "name": "Trifluridine and Tipiracil Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2022-01-10", "completion_date": "2023-06-11", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-11-11T16:47:06.992Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05130060" }, { "nct_id": "NCT03616483", "title": "The Indiana Myeloma Registry", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Plasma Cell Dyscrasias" ], "interventions": [ { "name": "This is a non-interventional trial", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Indiana University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2500, "start_date": "2018-06-18", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-10-29", "last_synced_at": "2026-11-11T16:47:06.992Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03616483" }, { "nct_id": "NCT00550082", "title": "3 Screen Electronic Alert", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Deep Vein Thrombosis", "Pulmonary Embolism", "Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 880, "start_date": "2007-07", "completion_date": "2009-11", "has_results": false, "last_update_posted_date": "2012-02-10", "last_synced_at": "2026-11-11T16:47:06.992Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00550082" }, { "nct_id": "NCT04439279", "title": "Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Lymphoma", "Advanced Malignant Solid Neoplasm", "Hematopoietic and Lymphoid Cell Neoplasm", "Refractory Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Multiple Myeloma" ], "interventions": [ { "name": "Trametinib Dimethyl Sulfoxide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2015-08-12", "completion_date": "2027-03-31", "has_results": true, "last_update_posted_date": "2026-11-09", "last_synced_at": "2026-11-11T16:47:06.992Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04439279" }, { "nct_id": "NCT02148913", "title": "Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Cohort 1: Carfilzomib 15 mg/m2", "type": "DRUG" }, { "name": "Cohort 2: Carfilzomib 20 mg/m2", "type": "DRUG" }, { "name": "Cohort 2b: Carfilzomib 20 mg/m2", "type": "DRUG" }, { "name": "Cohort 3b: Carfilzomib 27 mg/m2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Corewell Health West", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2014-06", "completion_date": "2018-12", "has_results": true, "last_update_posted_date": "2024-07-26", "last_synced_at": "2026-11-11T16:47:06.992Z", "location_count": 1, "location_summary": "Grand Rapids, Michigan", "locations": [ { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02148913" } ] }